Low
₹
High
₹
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 206.59 | 751.01 |
| Expenses | N/A | N/A |
| PBT | 14.47 | 46.62 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 11.1 | 31.45 |
| Founded | 1982 |
|---|---|
| Managing Director | Rajendra R Shah |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,64,331.30 | 1,935.25 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,81,466.36 | 6,832.30 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,65,951.64 | 4,895.20 | 3,309.40 - 3,309.40 |
| Apollo Hospitals Enterprise Ltd. | 1,27,127.92 | 8,843.70 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,228.74 | 1,438.75 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,762.82 | 1,150.50 | 835.50 - 835.50 |
| Lupin Ltd. | 1,14,128.12 | 2,496.90 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,07,853.30 | 1,108.15 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,04,275.29 | 2,526.55 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,03,958.87 | 1,245.50 | 1,148.40 - 1,148.40 |
No Records Found
Mercury Laboratories has informed that pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and as per Company’s Code of Conduct for regulating, monitoring, reporting of trading by insiders, trading window for dealing in securities of the Company by the Designated Persons and their relatives shall remain closed with effect from Wednesday, July 01, 2026. The trading window shall remain closed till 48 hours after the announcement of the unaudited financial results of the Company for the quarter ended on June 30, 2026. The date of the Board Meeting for considering the unaudited financial results for the quarter ended on June 30, 2026 will be intimated in due course
The above information is a part of company’s filings submitted to BSE.
Gujarat Inject Kerala has informed that the meeting of the Board of Directors of the Company is scheduled on 15/07/2026, inter alia, to consider and approve consideration and approval of financial results.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Mercury Laboratories Ltd. is ₹809.00 as of 2026-07-10.
The market capitalisation of Mercury Laboratories Ltd. is ₹97.08 as of 2026-07-10.
The 1-year return of Mercury Laboratories Ltd. is -82.15% as of 2026-07-10.
The P/E ratio of Mercury Laboratories Ltd. is 31.25 as of 2026-07-12.
The 52-week high and low of Mercury Laboratories Ltd. are ₹976.00 and ₹620.55, respectively, as of 2026-07-10.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.